Migraine: The treatment paradigm has shifted. Have you? - On-demand webinar
You need to login to participate in this education.
This education is accredited: RACGP 2 CPD, ACRRM 1.00 CME PD.
Migraine is the most common cause of headache presentations to general practice, and has significant personal and social costs. This on-demand webinar explores the changing treatment paradigm for migraine in light of precision medicine and the development of CGRP monoclonal antibodies, and explores how we can develop a new holistic, preventive approach to migraine management.
Upon completion of this activity the participant should be able to:
- Distinguish between vasculopathic vs. neuropathic models of migraine pathophysiology.
- Where appropriate, apply a preventive approach to migraine as opposed to primarily managing symptoms.
- Evaluate the use of newer agents for migraine, including CGRP mAbs.
- Implement holistic, individualised care for patients experiencing migraine.
This activity is sponsored by Eli Lilly Australia.
|Migraine: The treatment paradigm has shifted. Have you? - Education|
|Migraine: The treatment paradigm has shifted. Have you? - Evaluation|